Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/7/2025 | $200.00 | Outperform | Raymond James |
1/6/2025 | $173.00 | Buy → Neutral | BofA Securities |
10/14/2024 | $155.00 → $215.00 | Hold → Buy | Jefferies |
4/29/2024 | Mkt Perform → Outperform | William Blair | |
1/3/2024 | $125.00 → $150.00 | Neutral → Outperform | Robert W. Baird |
1/20/2022 | $150.00 → $126.00 | Equal-Weight | Morgan Stanley |
12/22/2021 | $162.00 → $156.00 | Overweight | Wells Fargo |
12/20/2021 | $148.00 → $145.00 | Buy | Deutsche Bank |
Raymond James initiated coverage of AptarGroup with a rating of Outperform and set a new price target of $200.00
BofA Securities downgraded AptarGroup from Buy to Neutral and set a new price target of $173.00
Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is August 14, 2025 to stockholders of record as of July 24, 2025. As previously announced, Aptar will hold a conference call on Friday, August 1, 2025 at 8:00 a.m. Central Time to discuss the Company's second quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. A
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501642213/en/Aptar Reports First Quarter 2025 Results First Quarter 2025 Highlights (compared to the prior year quarter) Reported sales of $887 million, a 3% decrease, and reported net income of $79 million, a 5% decrease Core sales were flat and adjusted EBITDA increased 3% from the prior year to $183 mill
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is May 22, 2025, to stockholders of record as of May 1, 2025. As previously announced, Aptar will hold a conference call on Friday, May 2, 2025 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. About Aptar
Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g
11-K - APTARGROUP, INC. (0000896622) (Filer)
SD - APTARGROUP, INC. (0000896622) (Filer)
S-8 - APTARGROUP, INC. (0000896622) (Filer)
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is August 14, 2025 to stockholders of record as of July 24, 2025. As previously announced, Aptar will hold a conference call on Friday, August 1, 2025 at 8:00 a.m. Central Time to discuss the Company's second quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. A
Dual-active material science solution is ideal for sensitive formulations AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has developed a dual-active material science technology engineered to simultaneously control moisture and oxygen. This technology is designed to provide a singular solution to address these degradation drivers for pharmaceutical drugs, including oral solid dose glucagon-like peptide-1 (GLP-1), medical devices and more. This new solution marks a significant material science breakthrough in the pharmaceutical industry, extending Aptar CSP Technologies' 3-Phase Activ-Polym
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it will present at two upcoming investor conferences: The William Blair 45th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 3, 2025. Stephan Tanda, President and CEO, and Vanessa Kanu, Executive Vice President and CFO, will present at 9:40 a.m. Eastern Time. The Jefferies Global Healthcare Conference on Wednesday, June 4, 2025. Stephan Tanda, President and CEO, and Vanessa Kanu, Executive Vice President and CFO, will present at 2:00 p.m. Eastern Time. A live audio webcast and presentations materials from these events will be
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)